The selection of RESI, the largest biomedical innovation early investment conference in North America, has been announced. Taiwan’s Yihua Biotechnology won the second place in the world. Xu Zengru, director of the School and Park Business Division, Huang Zhonger, chairman of Yihua Biotechnology, Chen Zongquan, vice chairman of the National Science and Technology Council, and Chen Huiqiong, deputy director of the Industrial Development Division of the National Development Council.

(Provided by the National Science Council)

[Reporter Wu Baixuan/Taipei Report] Good news for Taiwan's medical research innovation!

The National Science Council announced this afternoon (11th) that 10 teams from Taiwan were shortlisted for the largest biomedical innovation early stage investment conference (RESI) in North America this year, and Yihua Biotechnology Company won the second place in the world. The company uses liquid Biopsy technology combined with semiconductor biomedical chips, AI-assisted judgment, etc., can detect rare target cells in blood, and can be applied to gene and protein research.

According to the National Science Council, the world's largest biomedical investment forum (JP Morgan Healthcare Conference) is held every year in San Francisco, the United States. RESI is the largest early-stage investment conference for biotech innovations, and selects potential biomedical startups. Taiwan this year has 10 teams were shortlisted for the global finals, the results were announced yesterday, and finally Yihua Biotech won the second place in the world.

Please read on...

The National Science Council pointed out that RESI covers online matchmaking platforms, innovation challenges, and investor seminars, gathering venture capital funds, private equity funds, angel investment groups, etc.; and this time Taiwan Yihua Biotechnology Company won the second place in the world, It mainly develops the next-generation rare cell extraction and analysis system, using liquid biopsy technology with semiconductor biomedical chips, AI-assisted judgment, etc., to detect rare target cells in blood, and to apply gene and protein research to facilitate future precision medical analysis.

Huang Zhonger, chairman of Yihua Biotechnology, said that Yihua's award also means that Taiwan's semiconductor application and artificial intelligence technology has been recognized internationally. The company will enter the US market in the second half of the year. into the U.S. healthcare system.

Chen Zongquan, vice chairman of the National Science Council, was also invited by RESI to be the award presenter this year, and a total of 10 teams from Taiwan were shortlisted, including Shentong Biomedicine, Yihua Biotechnology, Juyi Wisdom, Samoa Johnny, etc., which shows that Taiwan's scientific research innovation Diversified scientific and technological strength in the medical field.

Taiwan's shortlisted teams are filled with many new biomedical technologies, such as Renhui International's innovative absorbable biomedical materials, which reduce pet postoperative pain; Jingtuo Biotech focuses on the analysis of circulating tumor cells and develops personalized anticancer drug detection; Xiongxin Technological research and development of AI care identification services, elderly fall prevention systems, etc.; neuron technology uses computer vision and AI analysis to identify patients with stroke and cranial nerve diseases.

☆Health news will never be missed, click like to follow the fan page.


☆For more important medical news, please go to Liberty Health.com.

keywords

  • the tumor

  • elder

  • medical technology

  • neurological disease

related news